文献速递心脑血管急症消化、代谢与肾脏急症

吸烟高血压患者强化血压管理的危害风险:SPRINT试验二次分析

Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
PubMed 文献 · JAMA Netw Open · 2019-03-01
一句话结论SPRINT二次分析提示,基线收缩压>144 mmHg的当前吸烟者接受强化降压(目标<120 mmHg)心血管事件和急性肾损伤风险更高,作者认为需进一步研究。

该研究为SPRINT试验的探索性、假设生成性二次分析,纳入9361例参与者,用半量数据随机森林分析筛选异质性效应,余量数据Cox回归验证。在测试数据集中,基线当前吸烟且收缩压>144 mmHg的110例强化治疗组主要复合心血管终点发生率为10.9%(12/110),标准治疗组126例为4.8%(6/126),HR 10.6(95%CI 1.3-86.1,P=0.03),3.3年需伤害人数43.7;该亚组急性肾损伤发生率强化组10.0%(11/110)vs 标准组3.2%(4/126),HR 9.4(95%CI 1.2-77.3,P=0.04)。作者结论认为该亚组强化降压心血管事件更高,需进一步研究评估权衡。

要点

  • 基线当前吸烟且收缩压>144 mmHg者,强化降压(目标<120 mmHg)vs 标准降压(目标<140 mmHg)主要心血管复合终点10.9%(12/110)vs 4.8%(6/126),HR 10.6(95%CI 1.3-86.1,P=0.03),需伤害人数43.7(3.3年)。
  • 同一亚组强化降压组急性肾损伤发生率10.0%(11/110)vs 标准组3.2%(4/126),HR 9.4(95%CI 1.2-77.3,P=0.04)。
  • 该分析为探索性、假设生成性二次分析,仅基于SPRINT测试数据集110例和126例亚组结果,作者结论为需进一步研究评估强化降压在该人群的权衡。

适用人群与场景

  • SPRINT试验参与者9361例,本次分析聚焦基线当前吸烟且收缩压>144 mmHg的466例(5.0%),其中训练数据集230例(49.4%),测试数据集236例(50.6%);测试数据集286例(61.4%)为男性,平均(SD)年龄60.7(7.2)岁。

诊断标准与关键阈值

  • 亚组识别标准:基于随机森林分析的2个协变量组合(基线吸烟状态和收缩压),区分出对干预反应不同的参与者。

处置流程与药物剂量

  • 强化治疗组收缩压目标<120 mmHg,标准治疗组收缩压目标<140 mmHg。

研究设计与关键结果

  • 研究类型:SPRINT随机试验的探索性、假设生成性、事后二次分析;原始试验在美国102个中心于2010年11月至2013年3月开展,本分析于2016年11月至2017年8月进行。
  • 方法:用半量试验数据以随机森林分析识别潜在异质性治疗效应,余量数据用Cox比例风险回归模型验证。
  • 主要复合心血管终点:心肌梗死、其他急性冠脉综合征、卒中、心力衰竭或心血管原因死亡。
  • 测试数据集:基线当前吸烟且收缩压>144 mmHg者,强化治疗组主要终点事件10.9%(12/110)vs 标准治疗组4.8%(6/126),HR 10.6(95%CI 1.3-86.1,P=0.03),3.3年需伤害人数43.7。
  • 测试数据集:同一亚组急性肾损伤事件强化治疗组10.0%(11/110)vs 标准治疗组3.2%(4/126),HR 9.4(95%CI 1.2-77.3,P=0.04)。

证据类型、等级与局限

  • 证据类型:随机对照试验(SPRINT)的探索性、假设生成性、事后二次分析;分析基于随机森林筛选和Cox回归验证。
  • 局限:原文未报告局限性;作者结论指出需进一步研究评估强化血压控制对高血压吸烟者的潜在权衡。

对床旁实践的改变

  • 作者认为,对于基线当前吸烟且收缩压>144 mmHg的高血压患者,强化降压治疗组心血管事件风险高于标准治疗组,需进一步研究评估该人群强化降压的潜在权衡。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The randomized Systolic Blood Pressure Intervention Trial (SPRINT) showed that lowering systolic blood pressure targets for adults with hypertension reduces cardiovascular morbidity and mortality in general. However, whether the overall benefit from intensive blood pressure control masks important heterogeneity in risk is unknown.

OBJECTIVE: To test the hypothesis that the overall benefit observed in SPRINT masked important heterogeneity in risk from intensive blood pressure control.

DESIGN, SETTING, AND PARTICIPANTS: In this exploratory, hypothesis-generating, ad hoc, secondary analysis of data obtained from 9361 participants in SPRINT, a random forest-based analysis was used to identify potential heterogeneous treatment effects using half of the trial data. Cox proportional hazards regression models were applied to test potential heterogeneous treatment effects on the remaining data. The original trial was conducted at 102 sites in the United States between November 2010 and March 2013. This analysis was conducted between November 2016 and August 2017.

INTERVENTIONS: Participants were assigned a systolic blood pressure target of less than 120 mm Hg (intervention treatment) or of less than 140 mm Hg (standard treatment).

MAIN OUTCOMES AND MEASURES: The primary composite cardiovascular outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes.

RESULTS: Of 9361 participants in SPRINT, 466 participants (5.0%) were current smokers with systolic blood pressure greater than 144 mm Hg at baseline, with 230 participants (49.4%) randomized to the training data set and 236 participants (50.6%) randomized to the testing data set; 286 participants (61.4%) were male, and the mean (SD) age was 60.7 (7.2) years. Combinations of 2 covariates (ie, baseline smoking status and systolic blood pressure) distinguished participants who were differentially affected by the intervention. In the testing data, Cox proportional hazards models for the primary outcome revealed a number needed to harm of 43.7 to cause 1 event across 3.3 years among participants who, at baseline, were current smokers with systolic blood pressure greater than 144 mm Hg (10.9% [12 of 110] of primary outcome events for intervention treatment vs 4.8% [6 of 126] for standard treatment; hazard ratio, 10.6; 95% CI, 1.3-86.1; P = .03). This subgroup was also associated with a higher likelihood to experience acute kidney injury under intensive blood pressure control (with a frequency of 10.0% [11 of 110] of acute kidney injury events for intervention treatment vs 3.2% [4 of 126] for standard treatment; hazard ratio, 9.4; 95% CI, 1.2-77.3; P = .04).

CONCLUSIONS AND RELEVANCE: In this secondary analysis of SPRINT data, current smokers with a baseline systolic blood pressure greater than 144 mm Hg had a higher rate of cardiovascular events in the intensive treatment group vs the standard treatment group. Further research is needed to evaluate the potential tradeoffs of intensive blood pressure control in hypertensive smokers.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Scarpa J, Bruzelius E, Doupe P, et al. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. JAMA Netw Open. 2019. PMID: 30848803. doi:10.1001/jamanetworkopen.2019.0005

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。